e research, dedicating most of the past 15 years of research to develop efficacious and beneficial therapeutic approaches for children afflicted by Canavan Disease, which is a pediatric neurogenetic disease, aggressively progressive, severely debilitating and uniformly fatal. This dedication has resulted in one

CHOP (PA) and recommendations for therapies are currently conducted in collaboration with neurologists at NYU (NY). My basic/clinical research for Canavan Disease has been funded by the NIH as well as charitable Foundations. Jacob's Cure, NY, stands out as one of the most successful fundraiser and supporter of